



## ASX ANNOUNCEMENT

23 October 2020

### **Notification under section 708A(5)(e) of the *Corporations Act 2001* (Cth)**

ImpediMed Limited (ASX: IPD) (**ImpediMed, Company**) gives this notice in accordance with section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

ImpediMed has issued 203,776 new fully paid ordinary shares to non-executive directors pursuant to approval received by shareholders at the annual general meeting held on 12 November 2019 and executives that have elected to receive 20% of their FY20 STI payout as shares in lieu of cash.

ImpediMed advises that:

1. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act and without a Product Disclosure Statement for the shares being prepared;
2. This notice is being given under section 708A(5)(e) of the Corporations Act;
3. As a disclosing entity, ImpediMed is subject to regular reporting and disclosure obligations;
4. As at the date of this notice, ImpediMed has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) section 674 of the Corporations Act as it applies to the Company; and
5. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under 708A(6)(e) of the Corporations Act.

For and on behalf of the Board.

Leanne Ralph  
Company Secretary

**Authorised for release by the Board of Directors of ImpediMed Limited.**

#### **Contact Details**

##### **Investor Relations Contact:**

Mike Bassett, ImpediMed

T : +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

##### **Media Contact:**

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: [kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)

**About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).